A comprehensive analysis of the dynamic biological networks in hcv induced hepatocarcinogenesis

PLoS ONE

Volumn 6, Issue 4, 2011, Pages

  He, Bing ^a   Zhang, Hao ^b   Shi, Tieliu ^a,c  

^a EAST CHINA NORMAL UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

^c INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 1; HLA DQA1 ANTIGEN; HLA DQB1 ANTIGEN;

ARTICLE; CANCER GROWTH; CELL PROLIFERATION; CYTOKINE PRODUCTION; DISEASE COURSE; GENE EXPRESSION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MICROARRAY ANALYSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; TRANSCRIPTION REGULATION; LIVER TUMOR; METABOLISM; PATHOLOGY; PHYSIOLOGY; VIROLOGY;

HEPATITIS C VIRUS;

CARCINOMA, HEPATOCELLULAR; DISEASE PROGRESSION; HEPACIVIRUS; HEPATITIS C; HUMANS; LIVER NEOPLASMS; METABOLIC NETWORKS AND PATHWAYS;

EID: 79955417840     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0018516     Document Type: Article

References (49)

1. Parkin DM, Bray F, Ferlay J, Pisani P, (2005) Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108.
2. Sangiovanni A, Del Ninno E, Fasani P, De Fazio C, Ronchi G, et al. (2004) Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance. Gastroenterology 126: 1005-1014.
3. HAN Z G, (2009) Recent progress in genomic research of liver cancer. Sci China Ser C-Life Sci 2009, 52 (1): 24-30.
4. Farazi PA, DePinho RA, (2006) Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 6: 674-687.
5. Niederau C, Heintges T, Lange S, Goldmann G, Niederau CM, et al. (1996) Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 334: 1422-1427.
6. Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, et al. (1997) Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 112: 463-472.
7. Niederau C, Lange S, Heintges T, Erhardt A, Buschkamp M, et al. (1998) Prognosis of chronic hepatitis C: results of a large, prospective cohort study. Hepatology 28: 1687-1695.
8. Degos F, Christidis C, Ganne-Carrie N, Farmachidi JP, Degott C, et al. (2000) Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death. Gut 47: 131-136.
9. Sun CA, Wu DM, Lin CC, Lu SN, You SL, et al. (2003) Incidence and cofactors of hepatitis C virus-related hepatocellular carcinoma: a prospective study of 12,008 men in Taiwan. Am J Epidemiol 157: 674-682.
10. Yoshida H, Shiratori Y, Moriyama M, Arakawa Y, Ide T, et al. (1999) Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. Ann Intern Med 131: 174-181.
11. Hartwell LH, Hopfield JJ, Leibler S, Murray AW, (1999) From molecular to modular cell biology. Nature 402: C47-52.
12. Stelzl U, Worm U, Lalowski M, Haenig C, Brembeck FH, et al. (2005) A human protein-protein interaction network: a resource for annotating the proteome. Cell 122: 957-968.
13. Zhou HJ, Liu YK, Li Z, Yun D, Shun QL, et al. (2007) Analysing protein-protein interaction networks of human liver cancer cell lines with diverse metastasis potential. J Cancer Res Clin Oncol 133: 663-672.
14. Bray D, (2003) Molecular networks: the top-down view. Science 301: 1864-1865.
15. Kann MG, (2007) Protein interactions and disease: computational approaches to uncover the etiology of diseases. Brief Bioinform 8: 333-346.
16. He B, Qiu X, Li P, Wang L, Lv Q, et al. (2010) HCCNet: an integrated network database of hepatocellular carcinoma. Cell res 20: 732-734.
17. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, et al. (2000) Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet 25: 25-29.
18. Llovet JM, Burroughs A, Bruix J, (2003) Hepatocellular carcinoma. Lancet 362: 1907-1917.
19. Llovet JM, Bru C, Bruix J, (1999) Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 19: 329-338.
20. Liu C, Cheng B, (2007) Association of polymorphisms of human leucocyte antigen-DQA1 and DQB1 alleles with chronic hepatitis B virus infection, liver cirrhosis and hepatocellular carcinoma in Chinese. Int J Immunogenet 34: 373-378.
21. El-Chennawi FA, Auf FA, Metwally SS, Mosaad YM, El-Wahab MA, et al. (2008) HLA-class II alleles in Egyptian patients with hepatocellular carcinoma. Immunol Invest 37: 661-674.
22. Chiba T, Yokosuka O, Fukai K, Hirasawa Y, Tada M, et al. (2005) Identification and investigation of methylated genes in hepatoma. Eur J Cancer 41: 1185-1194.
23. Zhai Y, Zhou G, Deng G, Xie W, Dong X, et al. (2006) Estrogen receptor alpha polymorphisms associated with susceptibility to hepatocellular carcinoma in hepatitis B virus carriers. Gastroenterology 130: 2001-2009.
24. Yu RB, Hong X, Ding WL, Tan YF, Zhang YX, et al. (2008) The association between the genetic polymorphism of HLA-DQA1, DQB1, and DRB1 and serum alanine aminotransferase levels in chronic hepatitis C in the Chinese population. J Gastroenterol Hepatol 23: 1394-1402.
25. Hohler T, Gerken G, Notghi A, Knolle P, Lubjuhn R, et al. (1997) MHC class II genes influence the susceptibility to chronic active hepatitis C. J Hepatol 27: 259-264.
26. Inagaki Y, Truter S, Bou-Gharios G, Garrett LA, de Crombrugghe B, et al. (1998) Activation of Proalpha2(I) collagen promoter during hepatic fibrogenesis in transgenic mice. Biochem Biophys Res Commun 250: 606-611.
27. Zhao YP, Wang H, Fang M, Ji Q, Yang ZX, et al. (2009) Study of the association between polymorphisms of the COL1A1 gene and HBV-related liver cirrhosis in Chinese patients. Dig Dis Sci 54: 369-376.
28. Monnier J, Piquet-Pellorce C, Feige JJ, Musso O, Clement B, et al. (2008) Prokineticin 2/Bv8 is expressed in Kupffer cells in liver and is down regulated in human hepatocellular carcinoma. World J Gastroenterol 14: 1182-1191.
29. Langley PG, Hughes RD, Williams R, (1985) Increased factor VIII complex in fulminant hepatic failure. Thromb Haemost 54: 693-696.
30. Albornoz L, Alvarez D, Otaso JC, Gadano A, Salviu J, et al. (1999) Von Willebrand factor could be an index of endothelial dysfunction in patients with cirrhosis: relationship to degree of liver failure and nitric oxide levels. J Hepatol 30: 451-455.
31. Ferro D, Quintarelli C, Lattuada A, Leo R, Alessandroni M, et al. (1996) High plasma levels of von Willebrand factor as a marker of endothelial perturbation in cirrhosis: relationship to endotoxemia. Hepatology 23: 1377-1383.
32. Rake MO, Flute PT, Pannell G, Williams R, (1970) Intravascular coagulation in acute hepatic necrosis. Lancet 1: 533-537.
33. Knittel T, Neubauer K, Armbrust T, Ramadori G, (1995) Expression of von Willebrand factor in normal and diseased rat livers and in cultivated liver cells. Hepatology 21: 470-476.
34. Urashima S, Tsutsumi M, Nakase K, Wang JS, Takada A, (1993) Studies on capillarization of the hepatic sinusoids in alcoholic liver disease. Alcohol Alcohol Suppl 1B: 77-84.
35. Amitrano L, Guardascione MA, Brancaccio V, Margaglione M, Manguso F, et al. (2004) Risk factors and clinical presentation of portal vein thrombosis in patients with liver cirrhosis. J Hepatol 40: 736-741.
36. Wanless IR, Wong F, Blendis LM, Greig P, Heathcote EJ, et al. (1995) Hepatic and portal vein thrombosis in cirrhosis: possible role in development of parenchymal extinction and portal hypertension. Hepatology 21: 1238-1247.
37. Oka K, Tanaka K, (1979) Intravascular coagulation in autopsy cases with liver diseases. Thromb Haemost 42: 564-570.
38. Chakravarti S, (2002) Functions of lumican and fibromodulin: lessons from knockout mice. Glycoconj J 19: 287-293.
39. Chakravarti S, Magnuson T, Lass JH, Jepsen KJ, LaMantia C, et al. (1998) Lumican regulates collagen fibril assembly: skin fragility and corneal opacity in the absence of lumican. J Cell Biol 141: 1277-1286.
40. Krull NB, Gressner AM, (1992) Differential expression of keratan sulphate proteoglycans fibromodulin, lumican and aggrecan in normal and fibrotic rat liver. FEBS Lett 312: 47-52.
41. Funderburgh JL, Mitschler RR, Funderburgh ML, Roth MR, Chapes SK, et al. (1997) Macrophage receptors for lumican. A corneal keratan sulfate proteoglycan. Invest Ophthalmol Vis Sci 38: 1159-1167.
42. Wu F, Vij N, Roberts L, Lopez-Briones S, Joyce S, et al. (2007) A novel role of the lumican core protein in bacterial lipopolysaccharide-induced innate immune response. J Biol Chem 282: 26409-26417.
43. Nelson R, (2002) Steroidal oestrogens added to list of known human carcinogens. Lancet 360: 2053.
44. Coe JE, Ishak KG, Ross MJ, (1990) Estrogen induction of hepatocellular carcinomas in Armenian hamsters. Hepatology 11: 570-577.
45. Neuberger J, Forman D, Doll R, Williams R, (1986) Oral contraceptives and hepatocellular carcinoma. Br Med J (Clin Res Ed) 292: 1355-1357.
46. Huang J, (2009) Current progress in epigenetic research for hepatocarcinomagenesis. Sci China Ser C-Life Sci 52: 31-42.
47. Robbins PD, Horowitz JM, Mulligan RC, (1990) Negative regulation of human c-fos expression by the retinoblastoma gene product. Nature 346: 668-671.
48. Arbuthnot P, Kew M, Fitschen W, (1991) c-fos and c-myc oncoprotein expression in human hepatocellular carcinomas. Anticancer Res 11: 921-924.
49. Caselmann WH, (1995) Transactivation of cellular gene expression by hepatitis B viral proteins: a possible molecular mechanism of hepatocarcinogenesis. J Hepatol 22: 34-37.